Business · 27/10/2021Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for XENLETA Tablets Patent Extension
Summary
The US Food and Drug Administration has officially set a review period for a patent extension application for XENLETA tablets, following a submission to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →